Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2012

View Archived Issues

Phase II trial investigates effects of axitinib in metastatic melanoma

BioCryst reports on extension phase of BCX-4208 trial

Bristol-Myers Squibb announces planned acquisition

First-in-human data disclosed on ALT-801

Pearl Therapeutics completes phase IIb trials of COPD combination therapy

Otuska launches ophthalmic suspension in Japan

Amicus Therapeutics presents results from phase II study in Fabry's disease

BKM-120 assessed as monotherapy and in combination regimens in metastatic breast cancer

Novel antibacterial agents patented by U.S. universities

Roche prepares new series of phosphodiesterase 10A inhibitors

Abbott Laboratories and Enanta Pharmaceuticals present new HCV NS3 inhibitors

Novel anti-inflammatory agents discovered in U.K.

Afraxis presents new serine/threonine-protein kinase PAK inhibitors

Almirall presents novel phosphodiesterase 4 inhibitors

KalVista Pharmaceuticals and JDRF enter partnership

Endo Pharmaceuticals and BioDelivery Sciences sign agreement for pain therapy

Durect reports topline data on Posidur

Ensemble Therapeutics identifies unique small-molecule IL-17 antagonists

Adherex continues enrollment in phase II eniluracil regimen study

Shigamabs study reaches full enrollment

UCB reports encouraging topline data on Vimpat

Presidio Pharmaceuticals provides update on hepatitis C programs

Idenix Pharmaceuticals reports interim data from IDX-184 study

Leo Pharma in-licenses Virobay product

Rigel Pharmaceuticals advances two lead products to clinic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.